{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:47:36Z","timestamp":1787503656295,"version":"build-2736575974"},"reference-count":74,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.eprac.2025.09.203","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:43:41Z","timestamp":1759301021000},"page":"268-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Approach and Challenges for Patients With Advanced Radioiodine-Refractory Differentiated Thyroid Cancer"],"prefix":"10.1016","volume":"32","author":[{"given":"Dipen C.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Azaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Konda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2025.09.203_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.203_bib3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000502229","article-title":"2019 European thyroid association guidelines for the treatment and Follow-Up of advanced radioiodine-refractory thyroid cancer","volume":"8","author":"Fugazzola","year":"2019","journal-title":"Eur Thyroid J"},{"issue":"23","key":"10.1016\/j.eprac.2025.09.203_bib4","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.3390\/jcm13237161","article-title":"Pathogenesis and management strategies in radioiodine-refractory differentiated thyroid cancer: from molecular mechanisms toward therapeutic approaches: a comprehensive review","volume":"13","author":"Voinea","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.203_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/endrev\/bnad022","article-title":"Radiation-related thyroid cancer","volume":"45","author":"Saenko","year":"2024","journal-title":"Endocr Rev"},{"issue":"9","key":"10.1016\/j.eprac.2025.09.203_bib6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/genes10090709","article-title":"Molecular alterations in thyroid cancer: from bench to clinical practice","volume":"10","author":"Tirr\u00f2","year":"2019","journal-title":"Genes (Basel)"},{"issue":"23","key":"10.1016\/j.eprac.2025.09.203_bib7","doi-asserted-by":"crossref","first-page":"11752","DOI":"10.18632\/oncotarget.2555","article-title":"BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications","volume":"5","author":"Oikonomou","year":"2014","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.eprac.2025.09.203_bib8","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.7150\/thno.57689","article-title":"Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS","volume":"11","author":"Oh","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.203_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun Signal"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.203_bib10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/thy.2018.0597","volume":"29","author":"Tuttle","year":"2019","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.eprac.2025.09.203_bib11","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.diii.2021.04.004","article-title":"PET\/CT in the management of differentiated thyroid cancer","volume":"102","author":"Zampella","year":"2021","journal-title":"Diagn Interv Imag"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.203_bib12","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1038\/s41598-018-22656-4","article-title":"Predicting 131I-avidity of metastases from differentiated thyroid cancer using 18F-FDG PET\/CT in postoperative patients with elevated thyroglobulin","volume":"8","author":"Liu","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.eprac.2025.09.203_bib13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1758834014548188","article-title":"Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer","volume":"6","author":"Worden","year":"2014","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.203_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1634\/theoncologist.2015-0107","article-title":"Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas","volume":"21","author":"Wassermann","year":"2016","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.eprac.2025.09.203_bib15","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.203_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1530\/ERC-17-0016","article-title":"Timing of multikinase inhibitor initiation in differentiated thyroid cancer","volume":"24","author":"Brose","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"10.1016\/j.eprac.2025.09.203_bib17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/RLU.0000000000002193","article-title":"Prognostic value of FDG-PET\/CT metabolic parameters in metastatic radioiodine-refractory differentiated thyroid cancer","volume":"43","author":"Manohar","year":"2018","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eprac.2025.09.203_bib18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1530\/eje.0.1480395","article-title":"Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise?","volume":"148","author":"Gruning","year":"2003","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2025.09.203_bib19","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1089\/thy.2008.0371","article-title":"Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer","volume":"19","author":"Kebebew","year":"2009","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.203_bib20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/thy.2012.0393","article-title":"Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine\u2013refractory thyroid carcinoma","volume":"23","author":"Sherman","year":"2013","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.eprac.2025.09.203_bib21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1530\/EJE-09-0702","article-title":"Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma","volume":"161","author":"Hoftijzer","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2025.09.203_bib22","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1172\/JCI46382","article-title":"Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation","volume":"121","author":"Chakravarty","year":"2011","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.eprac.2025.09.203_bib23","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"Ho","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.203_bib24","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1078-0432.CCR-14-2915","article-title":"Redifferentiation of iodine-refractory BRAF V600E-Mutant metastatic papillary thyroid cancer with dabrafenib","volume":"21","author":"Rothenberg","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.203_bib25","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1210\/jc.2018-01478","article-title":"Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers","volume":"104","author":"Dunn","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"10.1016\/j.eprac.2025.09.203_bib26","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1158\/1078-0432.CCR-22-0437","article-title":"Enhancing radioiodine incorporation into radioiodine-refractory thyroid cancer with MAPK inhibition (ERRITI): a single-center prospective two-arm study","volume":"28","author":"Weber","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.eprac.2025.09.203_bib27","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","article-title":"A phase II redifferentiation trial with dabrafenib-trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-Mutated differentiated thyroid cancer","volume":"29","author":"Leboulleux","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.eprac.2025.09.203_bib28","first-page":"1124","article-title":"MERAIODE: A phase II redifferentiation trial with trametinib and 131I in metastatic radioactive iodine refractory RAS mutated differentiated thyroid cancer","volume":"33","author":"Leboulleux","year":"2023","journal-title":"Thyroid\u00ae"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.203_bib29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/thy.2021.0565","article-title":"Enhancing radioiodine incorporation in BRAF -Mutant, radioiodine-refractory thyroid cancers with vemurafenib and the Anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial","volume":"32","author":"Tchekmedyian","year":"2022","journal-title":"Thyroid"},{"issue":"16_suppl","key":"10.1016\/j.eprac.2025.09.203_bib30","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1200\/JCO.2022.40.16_suppl.6089","article-title":"Phase 2 of trametinib plus radioiodine in RAS- mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446)","volume":"40","author":"Burman","year":"2022","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.203_bib31","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1097\/RLU.0000000000004475","article-title":"Reversing \u201cFlip-Flop\u201d phenomenon of 131I and glucose avidity in RET-fusion positive radioiodine-refractory thyroid cancer lesions after treatment of pralsetinib","volume":"48","author":"Chan","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"11","key":"10.1016\/j.eprac.2025.09.203_bib32","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1007\/s00259-024-06747-1","article-title":"Successful radioiodine redifferentiation with selpercatinib in RET fusion-positive papillary thyroid carcinoma","volume":"51","author":"Weiler","year":"2024","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.203_bib33","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1089\/thy.2021.0524","article-title":"Redifferentiating effect of larotrectinib in NTRK -Rearranged advanced radioactive-iodine refractory thyroid cancer","volume":"32","author":"Groussin","year":"2022","journal-title":"Thyroid"},{"issue":"17","key":"10.1016\/j.eprac.2025.09.203_bib34","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1056\/NEJMc2023094","article-title":"Larotrectinib-enhanced radioactive iodine uptake in advanced thyroid cancer","volume":"383","author":"Groussin","year":"2020","journal-title":"N Engl J Med"},{"issue":"9940","key":"10.1016\/j.eprac.2025.09.203_bib35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.eprac.2025.09.203_bib36","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.eprac.2025.09.203_bib37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nrclinonc.2016.19","article-title":"Evolving molecularly targeted therapies for advanced-stage thyroid cancers","volume":"13","author":"Bible","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eprac.2025.09.203_bib38","author":"Patel"},{"issue":"6","key":"10.1016\/j.eprac.2025.09.203_bib39","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/er.2019-00007","article-title":"Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond","volume":"40","author":"Cabanillas","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.eprac.2025.09.203_bib40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-3-319-91442-8_5","article-title":"Cabozantinib: multi-Kinase inhibitor of MET, AXL, RET, and VEGFR2","volume":"211","author":"Gr\u00fcllich","year":"2018","journal-title":"Recent Results Cancer Res"},{"issue":"8","key":"10.1016\/j.eprac.2025.09.203_bib41","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.eprac.2025.09.203_bib42","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(12)70335-2","article-title":"Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial","volume":"13","author":"Leboulleux","year":"2012","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.eprac.2025.09.203_bib43","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0354","article-title":"Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy","volume":"31","author":"Brose","year":"2024","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"10.1016\/j.eprac.2025.09.203_bib44","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial","volume":"17","author":"Brose","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.eprac.2025.09.203_bib45","first-page":"1184","article-title":"Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.203_bib46","first-page":"467","article-title":"A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan","volume":"34","author":"Tahara","year":"2024","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.eprac.2025.09.203_bib47","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.3390\/cancers13081932","article-title":"NTRK fusion genes in thyroid carcinomas: clinicopathological characteristics and their impacts on prognosis","volume":"13","author":"Pekova","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.eprac.2025.09.203_bib48","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2025.09.203_bib49","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.203_bib50","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc3431","article-title":"Molecular pathogenesis and mechanisms of thyroid cancer","volume":"13","author":"Xing","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.203_bib51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41698-023-00347-2","article-title":"Genomic landscape of 891 RET fusions detected across diverse solid tumor types","volume":"7","author":"Parimi","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.203_bib52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.eprac.2025.09.203_bib53","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.203_bib54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/thy.2023.0363","article-title":"Pralsetinib in patients with advanced\/metastatic rearranged during transfection (RET)-altered thyroid cancer: updated efficacy and safety data from the ARROW study","volume":"34","author":"Subbiah","year":"2024","journal-title":"Thyroid"},{"issue":"7","key":"10.1016\/j.eprac.2025.09.203_bib55","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1089\/thy.2010.1646","article-title":"Genetic alterations in the phosphatidylinositol-3 Kinase\/Akt pathway in thyroid cancer","volume":"20","author":"Xing","year":"2010","journal-title":"Thyroid"},{"issue":"12","key":"10.1016\/j.eprac.2025.09.203_bib56","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1093\/annonc\/mdt379","article-title":"A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes","volume":"24","author":"Lim","year":"2013","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.eprac.2025.09.203_bib57","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1200\/JCO.2021.39.15_suppl.6076","article-title":"Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory h\u00fcrthle cell thyroid cancer (HCC) (Alliance A091302\/ITOG 1706)","volume":"39","author":"Sherman","year":"2021","journal-title":"JCO"},{"issue":"13","key":"10.1016\/j.eprac.2025.09.203_bib58","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.3390\/cancers15133449","article-title":"Analysis of expression of programmed cell death ligand 1 (PD-L1) and BRAFV600E mutation in thyroid cancer","volume":"15","author":"Sekino","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.203_bib59","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/thy.2016.0228","article-title":"Programmed death-ligand 1 expression in papillary thyroid cancer and its correlation with clinicopathologic factors and recurrence","volume":"27","author":"Shi","year":"2017","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.203_bib60","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12885-019-5380-3","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer","volume":"19","author":"Mehnert","year":"2019","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.eprac.2025.09.203_bib61","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1158\/1078-0432.CCR-23-3417","article-title":"Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers","volume":"30","author":"French","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.eprac.2025.09.203_bib62","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S1470-2045(22)00278-9","article-title":"Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)","volume":"23","author":"Agarwal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.eprac.2025.09.203_bib63","doi-asserted-by":"crossref","first-page":"6513","DOI":"10.1200\/JCO.2020.38.15_suppl.6513","article-title":"A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC)","volume":"38","author":"Lorch","year":"2020","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.203_bib64","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1210\/clinem\/dgae512","article-title":"Cabozantinib plus ipilimumab\/Nivolumab in patients with previously treated advanced differentiated thyroid cancer","volume":"110","author":"Konda","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.09.203_bib65","author":"Sherman"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.203_bib66","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1056\/NEJM197401242900404","article-title":"Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients","volume":"290","author":"Gottlieb","year":"1974","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.203_bib67","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1089\/thy.2023.0553","article-title":"A prospective cohort Study exploring the effect of lenvatinib planned drug holidays in treatment of differentiated thyroid cancer","volume":"34","author":"Tahara","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.eprac.2025.09.203_bib68","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev-pathol-020712-163923","article-title":"Cellular heterogeneity and molecular evolution in cancer","volume":"8","author":"Almendro","year":"2013","journal-title":"Annu Rev Pathol"},{"issue":"12","key":"10.1016\/j.eprac.2025.09.203_bib69","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1210\/jc.2005-0987","article-title":"BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer","volume":"90","author":"Xing","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2025.09.203_bib70","doi-asserted-by":"crossref","first-page":"E1130","DOI":"10.1210\/jc.2013-4048","article-title":"TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer","volume":"99","author":"Liu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"S1","key":"10.1016\/j.eprac.2025.09.203_bib71","first-page":"P1A","article-title":"Thyroglobulin does not correlate with response in radioactive iodine refractory (RAIR) BRAF mutated papillary thyroid cancer (PTC) treated with dabrafenib alone or in combination with trametinib (oral abstract 31)","volume":"27","author":"Konda","year":"2017","journal-title":"Thyroid"},{"issue":"12","key":"10.1016\/j.eprac.2025.09.203_bib72","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.3390\/ijms17122040","article-title":"HER2 analysis in sporadic thyroid cancer of follicular cell origin","volume":"17","author":"Ruggeri","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.203_bib73","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","article-title":"Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-Mutant thyroid carcinomas","volume":"3","author":"Montero-Conde","year":"2013","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.eprac.2025.09.203_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100332","article-title":"Somatostatin receptor type 2 and thyroid-stimulating hormone receptor expression in oncocytic thyroid neoplasms: implications for prognosis and treatment","volume":"36","author":"Gillis","year":"2023","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.203_bib76","first-page":"65","article-title":"Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study","volume":"32","author":"Ballal","year":"2022","journal-title":"Thyroid"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25012285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25012285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T15:44:14Z","timestamp":1770738254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25012285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1530891X25012285"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.09.203","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approach and Challenges for Patients With Advanced Radioiodine-Refractory Differentiated Thyroid Cancer","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.09.203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the AACE.","name":"copyright","label":"Copyright"}]}}